VOLUME 3 , ISSUE 1 ( January-April, 2024 ) > List of Articles
Uday B Khanolkar, Meemansa Kashyap Buch, Bagirath Raghuraman, Barendra Kumar Raut, Satish C Govind, Devi Prasad Shetty
Keywords : Tricuspid edge-to-edge repair, Tricuspid regurgitation, TricValve, Tricuspid valve insufficiency
Citation Information : Khanolkar UB, Buch MK, Raghuraman B, Raut BK, Govind SC, Shetty DP. TricValve: A Palliative Therapy for Inoperable Tricuspid Regurgitation. 2024; 3 (1):49-53.
DOI: 10.5005/jp-journals-10089-0109
License: CC BY-NC 4.0
Published Online: 30-04-2024
Copyright Statement: Copyright © 2024; The Author(s).
Patients having isolated severe tricuspid regurgitation (TR) due to primary or secondary etiology continue to suffer from right heart dysfunction with or without clinical manifestations of systemic venous congestion. They often do not respond to conventional medical therapy and show poor quality of life (QoL) outcome measures. The available options for the management of severe tricuspid valve regurgitation include surgical replacement of the tricuspid valve and/or its repair in cases undergoing concomitant left heart valve surgery, provided the patients belong to acceptable surgical risk and do not have overt right heart dysfunction (class I level C). Patients who do not qualify for surgical repair or replacement are candidates for medical management. Recent advances have introduced transcatheter options for the treatment of moderate to severe TR for improved outcomes of QoL and relief of symptoms. We present the case of a patient who underwent a TricValve implantation, which is a novel transcatheter-based heterotopic bicaval system for the management of severe functional TR.